Results 141 to 150 of about 53,272 (209)
Effectiveness of the National Immunisation Programme and the catch-up vaccination on the incidence of hepatitis B in China: an interrupted time series analysis from 2005 to 2019. [PDF]
BMJ Glob HealthMing BW +6 more
europepmc +1 more source
Editorial: The interaction of chronic viral infections and SARS-CoV-2 infection and its effect on the COVID-19 pathogenesis. [PDF]
Front MicrobiolJha HC, Uppal T, Dabral P, Verma SC.
europepmc +1 more source
Vaccination uptake and associated factors among HIV pre-exposure prophylaxis (PrEP) users: insights from a retrospective cross-sectional study. [PDF]
BMC Public HealthShapiro Ben David S +4 more
europepmc +1 more source
Nanoparticles Based Therapeutic Approaches in Oncogenic Viral Infections: A Review. [PDF]
Int J NanomedicineAhmed N, Abusalah MAHA, Abuarqoub AH.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Annual Review of Medicine, 1985
Purified from the plasma of hepatitis B carriers, hepatitis B surface antigen particles have been used in a vaccine to prevent hepatitis B. This plasma-derived vaccine is immunogenic, protective, and has an excellent safety record. Indications and strategies for preexposure and postexposure prophylaxis are reviewed.
I M, Jacobson, J L, Dienstag
openaire +3 more sources
Purified from the plasma of hepatitis B carriers, hepatitis B surface antigen particles have been used in a vaccine to prevent hepatitis B. This plasma-derived vaccine is immunogenic, protective, and has an excellent safety record. Indications and strategies for preexposure and postexposure prophylaxis are reviewed.
I M, Jacobson, J L, Dienstag
openaire +3 more sources
Vaccines to Prevent Viral Hepatitis
New England Journal of Medicine, 1997At least five different viruses cause hepatitis in humans. Two — hepatitis A virus (HAV) and hepatitis E virus (HEV) — are nonenveloped RNA viruses that are spread predominantly by fecal–oral transmission and cause acute self-limited disease.1,2 The others — hepatitis B virus (HBV), hepatitis delta virus (HDV), and hepatitis C virus (HCV) — are ...
S M, Lemon, D L, Thomas
openaire +2 more sources
Vaccines for prevention of viral hepatitis
Haemophilia, 1998Summary. At the end of the 20th century active immunization against hepatitis A and B has been introduced into routine medical practice. Therefore, patients at risk, and especially those with coagulation disorders, should be immunized at the earliest age possible.
C. A. Lee +5 more
openaire +2 more sources
2011
HAV and HBV are prevalent worldwide, cause significant morbidity and mortality, and are vaccine-preventable.
Melissa L. Diamantis, Stephen K. Tyring
openaire +1 more source
HAV and HBV are prevalent worldwide, cause significant morbidity and mortality, and are vaccine-preventable.
Melissa L. Diamantis, Stephen K. Tyring
openaire +1 more source
Viral hepatitis: Global goals for vaccination
Journal of Clinical Virology, 2012In countries where hepatitis A is highly endemic, exposure to hepatitis A virus (HAV) is almost universal before the age of 10 years, and large-scale immunization efforts are not required. In contrast, in areas of intermediate endemicity or in transition from high to intermediate endemicity, where transmission occurs primarily from person to person in ...
openaire +2 more sources